MARKET

BDSI

BDSI

BDSI
NASDAQ

Real-time Quotes | Nasdaq Last Sale

4.030
+0.190
+4.95%
After Hours: 4.030 0 0.00% 17:46 12/04 EST
OPEN
3.860
PREV CLOSE
3.840
HIGH
4.060
LOW
3.860
VOLUME
1.13M
TURNOVER
--
52 WEEK HIGH
7.21
52 WEEK LOW
2.850
MARKET CAP
407.48M
P/E (TTM)
29.20
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Opioid Use Disorder Market to Soar at 10.8% CAGR and Hit USD 4.50 Billion by 2026; Increasing Research in Opioids by Pharmaceuticals to Aid Market Expansion: Fortune Business Insights(TM)
The global Opioid Use Disorder Market size is projected to reach USD 4.50 billion by 2026, exhibiting a CAGR of 10.8% during the forecast period. Increasing addiction to opioids across the globe will be the central force driving the growth of this market, shares Fortune Business Insights(TM) in its recent report. The US National Institutes of Health (NIH) estimates that approximately 16 million people around the world are suffering from opioid use disorder (OUD).
GlobeNewswire · 11/23 12:14
BioDelivery Sciences to Participate in the Piper Sandler 32nd Annual Healthcare Conference
BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with serious and complex chronic conditions, today announced that Jeff Bailey, Chief Executive Officer, and Terry Coelho, Chief Financial Officer, will participate in a fireside chat and 1x1 investor meetings at the Piper Sandler 32 Annual Healthcare Conference.
GlobeNewswire · 11/20 13:33
BioDelivery Sciences to Participate in the Piper Sandler 32nd Annual Healthcare Conference
RALEIGH, N.C., Nov. 20, 2020 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with serious and complex chronic conditions, today announced that Jeff Bailey, Chief Executive Officer, and Terry Coelho, Chief Financial Officer, will participate in a fireside chat and 1x1 investor meetings at the Piper Sandler 32nd Annual Healthcare Conference. The pre-recorded fireside chat will be available for viewing beginning November 23rd through December 3rd by accessing the recording library on the Piper Sandler conference site. BDSI will be hosting 1x1 investor meetings on Wednesday, December 2nd and Thursday, December 3rd. Meetings may be requested exclusively via Piper Sandler.ABOUT BIODELIVERY SCIENCES INTERNATIONAL, INC.BioDelivery Sciences International, Inc. (NASDAQ: BDSI) is a commercial-stage specialty pharmaceutical company dedicated to patients living with chronic conditions. BDSI has built a portfolio of products that includes utilizing its novel and proprietary BioErodible MucoAdhesive (BEMA®) technology to develop and commercialize, either on its own or in partnership with third parties, new applications of proven therapies aimed at addressing important unmet medical needs. BDSI's marketed products address serious and debilitating conditions, including chronic pain and opioid-induced constipation.© 2020 BioDelivery Sciences International, Inc.  All rights reserved.Contact:Terry Coelho Chief Financial Officer BDSI_IR@bdsi.com Bob Yedid LifeSci Advisors (646) 597-6989 bob@lifesciadvisors.com
GlobeNewswire · 11/20 13:30
Is a BioDelivery Sciences (BDSI) Good Value Investor Stock?
Zacks · 11/17 14:40
BioDelivery Sciences to Present Virtually and Host 1x1 Investor Meetings at the Annual Southwest IDEAS Investor Conference on November 18
BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with serious and complex chronic conditions, today announced that Jeffrey Bailey, Chief Executive Officer, and Terry Coelho, Chief Financial Officer, will participate in the virtual Southwest IDEAS Investor Conference on November 18, 2020. BDSI's presentation will be webcasted and is scheduled to be available at 7:00 am CST on November 18. The presentation can be accessed through the Southwest IDEAS conference portal for registered participants, in the investor relations section of the Company's website: www.bdsi.com, and on the IDEAS conference website: www.IDEASconferences.com.
GlobeNewswire · 11/11 13:30
BioDelivery Sciences Reports Strong Q3 2020 Results
Total Company Net Revenue Increased 30% versus Prior Year Reaching a Record $39.4 Million
GlobeNewswire · 11/05 13:02
BioDelivery Sciences Announces $25 Million Share Repurchase Program
BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with serious and complex chronic conditions, today announced that its Board of Directors has authorized the repurchase of up to $25 million of the Company's shares of common stock.
GlobeNewswire · 11/04 22:31
BioDelivery Sciences Announces Appointment of Jeff Bailey as Permanent CEO
BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with serious and complex chronic conditions, today announced that its Board of Directors has appointed Jeff Bailey as permanent Chief Executive Officer (CEO), effective November 4, 2020. Jeff had previously been appointed as interim CEO in May 2020 while continuing to serve on the Board of Directors.
GlobeNewswire · 11/04 22:16
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of BDSI. Analyze the recent business situations of BDSI through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 8 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average BDSI stock price target is 8.00 with a high estimate of 9.00 and a low estimate of 7.00.
EPS
Institutional Holdings
Institutions: 225
Institutional Holdings: 78.69M
% Owned: 77.83%
Shares Outstanding: 101.11M
TypeInstitutionsShares
Increased
43
4.20M
New
30
-3.39M
Decreased
61
3.89M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+1.23%
Pharmaceuticals & Medical Research
+1.72%
Key Executives
Chairman/Independent Director
Peter Greenleaf
Chairman/Director
Francis O'Donnell
President
Scott Plesha
Chief Executive Officer
Jeffrey Bailey
Chief Financial Officer
Terry Coelho
Vice Chairman/Director
Mark Sirgo
Chief Financial Officer/Treasurer
Mary Coelho
Senior Vice President
Joseph Lockhart
Senior Vice President
Kevin Ostrander
Chief Compliance Officer/General Counsel/Secretary
James Vollins
Other
Thomas Smith
Independent Director
Todd Davis
Independent Director
Kevin Kotler
Independent Director
Vanila Singh
Director
W. Mark Watson
Independent Director
William Watson
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About BDSI
BioDelivery Sciences International, Inc. is a specialty pharmaceutical company. The Company develops and commercializes, either on its own or in partnerships with third parties, applications of approved therapeutics to address unmet medical needs using drug delivery technologies. The Company develops pharmaceutical products aimed principally in the areas of pain management and addiction. The Company's products utilize the BioErodible MucoAdhesive (BEMA) drug delivery technology, a small, erodible polymer film for application to the buccal mucosa (the lining inside the cheek). The Company's United Sates Food and Drug Administration (FDA) approved product, ONSOLIS (fentanyl buccal soluble film), as well as its approved products BUNAVAIL (buprenorphine and naloxone buccal film) buccal film and BELBUCA (buprenorphine) buccal film, utilize BEMA technology.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of BioDelivery Sciences International, Inc. stock information, including NASDAQ:BDSI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BDSI stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading BDSI stock methods without spending real money on the virtual paper trading platform.